Key points
Background
Methods
Study population and variables
Statistical analysis
Results
Baseline characteristics
Baseline characteristic | Patients who received HCV treatment (n = 17) | Patients who did not receive HCV treatment (n = 48) | All patients (N = 65) |
---|---|---|---|
Male sex - n (%) | 13 (76) | 30 (62) | 43 (66) |
Age, years – median (IQR) | 46 (42–49) | 46 (43–50) | 46 (43–50) |
HIV acquired by IDU – n (%) | 12 (70) | 45 (94) | 57 (88) |
Nadir, cells/mm3 – median (IQR) | 199 (76–292) | 121 (45–225) | 136 (52–242) |
CD4+ cells/mm3 – median (IQR) | 294 (216–482) | 258 (160–423) | 293 (165–424) |
CDC disease category C (%) | 6 (35) | 16 (33) | 22 (34) |
cART (%) | 16 (94) | 40 (83) | 56 (86) |
HIV-RNA < 5 0 copies/mL (%) | 10 (59) | 37 (77) | 47 (71) |
HBsAg-positive – n (%) | 0 (0) | 5(10) | 5 (8) |
Alcohol intake > 50 g/day – n (%) | 2 (12) | 11 (23) | 13 (20) |
First decompensation – n (%) | |||
Ascites | 14 (82) | 40 (83) | 54 (83) |
Variceal bleeding | 2 (12) | 3 (6) | 5 (8) |
Hepatic encephalopathy | 0 (0) | 5 (10) | 5 (8) |
Non-obstructive jaundice | 1 (6) | 0 (0) | 1 (1) |
Hepatocellular carcinoma – median (IQR) | 1 (6) | 2 (4) | 3 (4.6) |
Esophageal varices – n (%) | |||
Yes | 5 (29) | 25 (52) | 30 (15) |
No | 8 (47) | 9 (19) | 17 (2) |
Unknown | 4 (23) | 14 (29) | 18 (28) |
Child-Pugh score – median (IQR) | 7 (5–9) | 7 (6–8) | 7 (5–8) |
MELD score – median (IQR) | 11 (7.5–15.5) | 11 (7–14) | 11 (7–14) |
Serum albumin, g/dL – median (IQR) | 3.5 (2.4–4.2) | 3.0 (2.5–3.7) | 3.1 (2.5–3.9) |
FIB-4 value – median (IQR) | 6.5 (3.1–13.5) | 6.4 (4.2–10.6) | 6.4 (3.8–10.6) |
Liver stiffness, kPa – median (IQR) | 50 (34–70) | 48 (35–63) | 48 (35–64) |
LSPS – median (IQR) | 8.8 (4.9–17.4) | 10.5 (8–16.3) | 10.3 (7.6–16.4) |
HCV genotype – median (IQR) | |||
1 | 12 (70) | 26 (54) | 38 (58) |
2 | 0 (0) | 1 (2) | 1 (1.5) |
3 | 3 (18) | 9 (19) | 12 (18.5) |
4 | 2 (12) | 3 (6) | 5 (7.7) |
Unknown | 0 (0) | 9 (19) | 9 (13.8) |
Follow-up
Predictors of mortality
Variable | Patients | AUROC (95% CI) | P Value |
---|---|---|---|
Serum albumin | 64 | 0.695 (0.566–0.825) | .007 |
Child-Pugh score | 65 | 0.648 (0.514–0.782) | .040 |
MELD score | 65 | 0.633 (0.494–0.772) | .065 |
Liver stiffness | 65 | 0.618 (0.482–0.755) | .100 |
LSPS | 55 | 0.595 (0.443–0.747) | .225 |
FIB-4 | 64 | 0.569 (0.428–0.710) | .343 |
Variable | Univariate Analysis | ||
---|---|---|---|
HR | 95% CI |
P
| |
Sex (male vs female) | 0.887 | 0.417–1.887 | .755 |
Age (per year) | 1.011 | 0.943–1.085 | .749 |
Year of decompensation (≤2008 vs > 2008) | 1.238 | 0.563–2.724 | .596 |
Alcohol intake > 50 g/day (yes vs no) | 1.232 | 0.522–2.905 | .634 |
HBsAg (positive vs negative) | 1.210 | 0.366–4.005 | .754 |
Nadir CD4+ (per cell/mm3) | 1.000 | 0.997–1.003 | .920 |
Baseline CD4+ (per cell/mm3) | 0.999 | 0.997–1.001 | .489 |
Esophageal varices (yes vs no) | 0.729 | 0.336–1.582 | .424 |
Liver stiffness (per kPa) | 1.017 | 0.998–1.037 | .078 |
Serum albumin (per g/dL) | 0.482 | 0.298–0.780 | .003 |
FIB-4 (per unit) | 1.095 | 1.024–1.171 | .008 |
Child-Pugh score (per unit) | 1.356 | 1.100–1.671 | .004 |
MELD score (per unit) | 1.111 | 1.022–1.209 | .014 |
LSPS (per unit) | 1.023 | 0.987–1.060 | .220 |
Anti-HCV therapya (no vs yes) | 1.340 | 0.300–5.920 | .695 |
aHR | 95% CI |
P
| |
---|---|---|---|
Model 1 | |||
Liver stiffness (per kPa) | 1.013 | 0.991–1.034 | .249 |
Serum albumin (per g/dL) | 0.530 | 0.280–1.001 | .050 |
FIB-4 (per unit) | 1.027 | 0.932–1.131 | .591 |
MELD (per unit) | 0.986 | 0.872–1.115 | .819 |
Model 2 | |||
Liver stiffness (per kPa) | 1.013 | 0.999–1.033 | .221 |
FIB-4 (per unit) | 1.028 | 0.936–1.129 | .568 |
Child-Pugh score (per unit) | 1.276 | 0.975–1.672 | .076 |
Model 3 | |||
Liver stiffness (per kPa) | 1.013 | 0.992–1.035 | .225 |
Serum albumin (per g/dL) | 0.498 | 0.275–0.904 | .022 |
MELD (per unit) | 0.995 | 0.885–1.119 | .936 |
Model 4 | |||
Liver stiffness (per kPa) | 1.014 | 0.995–1.034 | .152 |
Child-Pugh score (per unit) | 1.338 | 1.080–1.656 | .008 |